Letters intended for publication should be a maximum of 500 words, 10 references, and one table or figure, and should be sent to the editor at the address given on the inside front cover. Those responding to articles or correspondence published in the journal should be received within six weeks of publication.

Listening between the lines: what BAT really thinks of its consumers in the developing world

In an audio recording of the “Structured Creativity Conference” held in Hampshire, UK in June 1984, British American Tobacco (BAT) adds context to the written report of marketing and product applications. Employees are taped brainstorming creative ways to push their product in light of future marketing constraints and social pressure towards a smoke-free society. Project proposals included the following: low sidestream smoke cigarettes, “front end lift” cigarette design to give the smoker more “impact” on the first puff, pleasant smelling sidestream smoke, and an ‘intimate’ delivery—“Forget about smoking...GO FOR A QUICKIE. No tar with nic, and nicotine inhalers—‘Forget about smoking...’

‘...What is of great interest to those of us who spend our time searching through page after page of internal tobacco industry documents is the significant difference between what is written and what is said. David Schechter, the former BAT lawyer, recently explained the “mental copy rule” to the US Department of Justice, which assumed that anything one would write could end up being used publicly or legally against the company. This leads to the obvious question: Are we overlooking important research tools in the form of non-written material?”

M E Muggli
R D Hurt
Correspondence to: Monique E Muggli, 1345 Osceola Avenue, St Paul, MN 55105, USA; mmuggli@attbi.com

Eclipse: does it live up to its health claims?

We read the recent article by Slade et al 1 with great interest and agree that reasonable regulation focused on the development and appropriate evaluation of potential reduced risk cigarettes is warranted. Furthermore, we agree with Slade et al that the results of our evaluation indicate that Eclipse may offer potential benefits to smokers. However, we disagree with several of the other conclusions drawn by the authors.

The article challenges the merits of Eclipse and questions the fundamental differences between Eclipse and other cigarettes. It is not possible within the context of this letter either to fully describe the scientific data that has been developed to characterise Eclipse or to address many of the criticisms of Eclipse raised in Slade’s article. However, we briefly address pertinent issues below and encourage interested parties to independently evaluate all of the available information.

Slade et al have inaccurately represented the claims that RJ Reynolds Tobacco Company (RJRT) has made regarding Eclipse. No cigarette is without risk, including Eclipse. Our advertising for Eclipse states: “The best choice for smokers who worry about their health is to quit. But Eclipse is the next best choice for those who have decided to continue smoking.” Our advertising also makes it clear that RJRT does not claim that Eclipse is risk free or less risk of cardiovascular disease or complications with pregnancy.

In the absence of any existing regulatory standard, RJRT assumed Eclipse’s risk reduction potential using a four-step scientific methodology that included chemical testing and analysis, biological and toxicological testing, human testing, and independent scientific verification. In general, the evaluation strategy utilised was consistent with strategies outlined by the Institute of Medicine that addressed this subject. 2

RJRT has conducted an extensive comparative evaluation of Eclipse and has presented this research at scientific meetings in both the USA and internationally. The results of these and other studies may be reviewed on the Eclipse website (www.eclipseScience.com).

In addition, much of this research has been published in the peer-reviewed literature. The weight of the evidence from this research clearly shows that, compared to other cigarettes, Eclipse may present smokers with less risk of cancer, chronic bronchitis, and possibly emphysema. An independent panel of scientific experts reviewed the science and reached conclusions consistent with RJRT’s claims. 3

RJRT’s comparative studies were conducted using Kentucky reference cigarettes (K1RF and K2RF) and leading low “tar” and low ultra low “tar” commercial brand styles. Combined, the cigarettes selected for comparison to Eclipse are representative of the vast majority of cigarettes sold in the US market. 4 By contrast the entire market segment of the very low yielding ultra low “tar” cigarettes used by Slade et al as a comparison collectively represent less than 1% of the market. Furthermore, one of the two cigarettes selected as a comparison (Now Box) does not have a measurable US Federal Trade Commission (FTC) “tar yield.”

References
Comparisons of Eclipse mainstream smoke constituent yields to the yields of very yielding ultra low "tar" cigarettes (Now Box and Carlton Soft Pack) obtained by machine smoking do not change the fact that Eclipse cigarettes may present smokers with less risk of certain smoking related diseases than other cigarettes. RJRT scientists have recently demonstrated Eclipse is significantly less mutagenic than either Carlton Soft Pack or Now Box over a wide range of machine smoking conditions. On a per cigarette basis, Eclipse was less mutagenic than Carlton Soft Pack under all machine smoking conditions tested and was less mutagenic than Now Box when evaluated using the machine smoking conditions mandated by both the Massachusetts Department of Health and the Canadian federal government. In addition, Eclipse was significantly less cytotoxic on both a per mg "tar" basis and a per cigarette basis under the same range of machine smoking conditions.

As noted by Slade et al., smokers typically take larger and more frequent puffs than those specified by the US Federal Trade Commission puffing regimen and they typically smoke Eclipse differently than their usual brand. Therefore, it is essential that a weight-mission puffing regimen and they typically conducted in smokers demonstrate that smokers are consistent with reductions in smoker exposure to smoke constituents under actual smoking conditions. Furthermore, additional studies conducted in smokers have demonstrated reductions in bronchial inflammation and inflammation of the lower lung when smoking Eclipse compared to Eclipse.1-4 These findings are consistent with reductions in smoker exposure to smoke constituents under actual smoking conditions and support RJRT’s conclusion that Eclipse may reduce the risks of certain smoking related diseases relative to other cigarettes currently on the market.

E J Swauger
RJ Reynolds Tobacco Co, Winston-Salem, North Carolina, USA

Correspondence to: James E Swauger, PO Box 1487, Winston-Salem, NC27102-1487, USA; swauger@rjrt.com

References
1 Slade J, Connelly GN, Lymperis D: Eclipse—does it live up to its health claims? Tobacco Control 2002;11 [suppl II]:i64–70.

Author’s reply

Swauger argues that based on the weight of the evidence, Eclipse, compared to other cigarettes, may present smokers with less risk of cancer and other diseases relative to their usual brand. Therefore, it is essential that a weight-mission puffing regimen and they typically conducted in smokers demonstrate that smokers are consistent with reductions in smoker exposure to smoke constituents under actual smoking conditions and support RJRT’s conclusion that Eclipse may reduce the risks of certain smoking related diseases relative to other cigarettes currently on the market.

J N Connolly
Massachusetts Department of Public Health, 250 Washington Street, Boston, MA 02108-4619, USA; greg.connolly@state.ma.us

Seasonality in cigarette sales: patterns and implications for tobacco control

Cigarette smoking is the leading public health problem in the USA, contributing to over 400,000 deaths a year.1 Given its importance, the tobacco control community should be aware of all significant patterns in the consumption of cigarettes, whether the season or other phenomena, including consumption. Unfortunately, little attention has been paid to the seasonal nature of smoking. Findings on seasonal patterns may have major implications for the timing of interventions designed to manage the tobacco problem, both in the USA and in other countries.

In this letter, monthly data for cigarette sales at the state level for the USA are analysed to test for the presence of seasonality and to characterise the phenomenon. The results reveal a seasonal pattern that is significant both in the statistical sense and in magnitude. This information may be relevant to efforts aimed at tobacco control, and in particular to efforts aimed at reducing smoking during the winter months of January and February, and an increase during the summer months of June, July, and August.2 Because seasonality in sales does not reflect seasonality in production, it must be inferred that the seasonality is driven by wholesale and retail phenomena, including consumption. The data used in this study are monthly figures for sales of cigarettes by wholesalers aggregated at the state level between January 1963 and July 2000. Until December 1997, the Tobacco Institute was responsible for their collection. For the period following this, the firm Orzechowski and Walker produced the data.3

www.tobaccocontrol.com

Tob Control: first published as 10.1136/tc.12.1.104-a on 1 March 2003. Downloaded from http://tobaccocontrol.bmj.com/ on June 9, 2022 by guest. Protected by copyright.
Two methodologies were used to examine seasonality. The first involved spectral analysis, which identifies cyclical patterns in the data. If a cycle of a particular length is revealed to be important, then a systematic phenomenon underlies the pattern. The second was the calculation of the seasonal factor range. The seasonal factor range is the ratio of the high month to the low month for any one year cycle in the data, the two months which had the highest and the two with the lowest seasonal indices were selected, and the seasonal factor range was calculated on the assumption that the series had been seasonally decomposed. This involved splitting the series into trend, seasonal, and irregular components. The seasonal component was extracted and was expressed as a percentage of the mean annual value for each state. Stable seasonal indices (column 2) were derived from the seasonal components. In percentage terms, the seasonal effect is large—as column 4 shows, the mean annual range (difference between high and low factors) across the 17 years is around 30%. To put this in perspective, assuming a price elasticity of −0.4, a 30% drop in sales would require a 75% increase in cigarette prices!

Next, to identify the months for which sales were uniformly high or low for any state, for any one year cycle in the data, the two months with the highest and the two with the lowest seasonal factors were selected. Using the seasonality analysis, a number of indicators were generated. The p values in table 1, column 3 correspond to the null hypotheses of no seasonal stability in sales. At a significance level of 5%, the null hypothesis of no seasonality is rejected for all the states.

In percentage terms, the seasonal effect is large—as column 4 shows, the mean annual range (difference between high and low factors) across the 17 years is around 30%. To put this in perspective, assuming a price elasticity of −0.4, a 30% drop in sales would require a 75% increase in cigarette prices!

Next, to identify the months for which sales were uniformly high or low for any state, for any one year cycle in the data, the two months with the highest and the two with the lowest seasonal components were selected, and the frequency of the appearance of the months in the “high-2” and “low-2” months was computed by state. Columns 5–8 show the most frequently appearing high and low months. February appears as a “low-2” month for all states, but one state, and June appears as a “high-2” month for 42 states. Figure 1 shows that the “high-2” and “low-2” months was confirmed by parallel analyses of production data and discussions with an expert on the production of tobacco. This pattern is seemingly contrary to the popular belief that smokers tend to smoke more in winter (perhaps to keep warm) and less in summer.
sales, and June, July, and August, a “high” season.

Possible causes of seasonality include the effect of climate on smoking behaviour (low in cold weather and high in mild weather, especially in view of now widespread indoor smoking restrictions across the USA), the timing of tax changes (December-January or June-July), the timing of the new fiscal year (June-July), the timing of school year (August-June), and the timing of quitting efforts tied to New Year’s resolutions (December-January). In the obvious extension to this research, the determinants of this potentially important statistical phenomenon will be analysed in detail.

The present findings demonstrate that sales of cigarettes in the USA have a strong seasonal component. This has potential implications for the timing of cessation initiatives and other time dependent policies. The phenomenon of seasonality could hold the key to significant advances in tobacco control and in the management of a leading public health problem.

S Chandra
Graduate School of Public and International Affairs, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

F J Chaloupka
Department of Economics, University of Illinois at Chicago, Chicago, Illinois, USA

Correspondence to: Siddharth Chandra, GSpIA, 3K2S Wesley W Posvar Hall, University of Pittsburgh, Pittsburgh, PA 15260, USA; schandra@pitt.edu

Acknowledgments

The authors gratefully acknowledge the support of the Substance Abuse Policy Research Program of the Robert Wood Johnson Foundation for supporting this work. Comments from Jonathan Caulkins and the excellent research assistance of Ascarya and Djimatudin Abubakar are also gratefully acknowledged.

References

3 Orzechowski W, Walker RC. Monthly state-level data on tax-paid cigarette sales. Electronic file provided to Frank Chaloupka. (See also, for example, Orzechowski W, and Walker RC. The tax burden on tobacco: historical compilation, 1999. Arlington, Virginia: Orzechowski and Walker.)

Way-out developments at BATCO

Working in tobacco control, it is easy to get the impression that the tobacco industry is a united front, with all parties carefully avoiding internal divisions that might undermine the greater struggle against the “antis”. However, tobacco industry documents that have been made public as a result of litigation in the USA frequently reveal ruthless competition for market share, as well as intense suspicion about competitors’ activities. This was brought home to us recently when reading a 1977 document on “developments in the scientific field” by Dr Sydney J Green, then British American Tobacco’s (BAT’s) senior scientist for research and development.1

After several pages of unremarkable reports on industry and external research on low tar cigarettes and smoking and health, Green informed his readers about two “way-out” developments at BAT:

• Way-out development 1: “A way-out development is that of compounds (such as etorphine) which are 10,000 times as effective as analgesics [such as morphine and which are very addictive. It is theoretically possible (if politically unthinkable) to add analytically undetectable quantities of such materials to cigarettes to create brand allegiance. But this thought may suggest the possibility of such compounds occurring naturally.” We are grateful to Dr Green for clarifying what “brand allegiance” really means for the tobacco industry.

• Way-out development 2: “Another way-out development, which arises from work done in a quite different area, is that it would now be quite feasible and quite inexpensive to produce an unacceptable off-taste in cigarettes from some factories for a prolonged period without approaching nearer than half to one mile.”

In the same spirit of scientific curiosity which no doubt motivated the BATCO researchers, we would be very interested to know the formula for this substance. On a more serious note, while we were not able to come up with any plausible candidates for a substance that could make way-out development 2 feasible, we are concerned that Green was right about the feasibility of adding etorphine or some other addictive substance to cigarettes.

Green’s report followed an earlier memo from Keith D Kilburn to CI Ayres,2 expressing

Figure 1

Months with high and low seasonal factors (with possible reasons for prominent months).

Way-out developments at BATCO

Working in tobacco control, it is easy to get the impression that the tobacco industry is a united front, with all parties carefully avoiding internal divisions that might undermine the greater struggle against the “antis”. However, tobacco industry documents that have been made public as a result of litigation in the USA frequently reveal ruthless competition for market share, as well as intense suspicion about competitors’ activities. This was brought home to us recently when reading a 1977 document on “developments in the scientific field” by Dr Sydney J Green, then British American Tobacco’s (BAT’s) senior scientist for research and development.1 After several pages of unremarkable reports on industry and external research on low tar cigarettes and smoking and health, Green informed his readers about two “way-out” developments at BAT:

• Way-out development 1: “A way-out development is that of compounds (such as etorphine) which are 10,000 times as effective as analgesics [such as morphine and which are very addictive. It is theoretically possible (if politically unthinkable) to add analytically undetectable quantities of such materials to cigarettes to create brand allegiance. But this thought may suggest the possibility of such compounds occurring naturally.” We are grateful to Dr Green for clarifying what “brand allegiance” really means for the tobacco industry.

• Way-out development 2: “Another way-out development, which arises from work done in a quite different area, is that it would now be quite feasible and quite inexpensive to produce an unacceptable off-taste in cigarettes from some factories for a prolonged period without approaching nearer than half to one mile.”

In the same spirit of scientific curiosity which no doubt motivated the BATCO researchers, we would be very interested to know the formula for this substance. On a more serious note, while we were not able to come up with any plausible candidates for a substance that could make way-out development 2 feasible, we are concerned that Green was right about the feasibility of adding etorphine or some other addictive substance to cigarettes.

Green’s report followed an earlier memo from Keith D Kilburn to CI Ayres,2 expressing

Figure 1

Months with high and low seasonal factors (with possible reasons for prominent months).
concern about what BATCO’s competitors might be doing to their “low delivery ciga-
rettes” (that is, low machine measured tar and nicotine yield cigarettes) in order to create brand allegiance. Kilburn proposed that a regular etorphine dose of as little as 0.2 μg per
day would be sufficient to create an addictive craving for the source. He also claimed that the required delivery of around 7 ng per ci-
garette (or around half the delivery of ben-
zo[a]pyrene) would be analytically difficult to measure.

Etorphine is a powerful drug with heroin-
like effects, which include respiratory failure in the case of overdose. It may be more famil-
 iar to readers as “elephant juice”—a veteri-
ary drug with such high potency that a tiny
quantity injected from a dart can immobilise
an elephant.

The dangers of etorphine to humans have been dramatically demonstrated in incidents
during veterinary use, as there have been fatal
overdoses to veterinarians attempting to dart
dark unruly animals. Reputedly, a mere
scratch from an etorphine dart has been suf-
cient in some cases to provide a fatal
overdose. As a consequence of these fatalities,
veterinarians who are registered to use
eorphine must now have an assistant stand-
ing by with a dose of an etorphine antagon-
lar to hand.

These observations on the dangers of
eorphine underscore Green’s and Kilburn’s
essential point: very low concentrations of
etorphine must now have an assistant stand-
ing by with a dose of an etorphine antagonist
in hand.

W King, R Borland VicHealth Centre for Tobacco Control, the Cancer
Council Victoria, Victoria, Australia
M Christie Department of Pharmacology and The Medical
Foundation, University of Sydney, Sydney, New
South Wales, Australia

Correspondence to: Bill King, VicHealth Centre for
Tobacco Control, the Cancer Council Victoria,
1 Rathdowne St, Carlton, Victoria 3053, Australia;
bill.king@cancervic.org.au

References
1 Green SJ. C.A.C. – Saloman. S & H Item
18 April 1977. Bates No. 110069827. URL:
www.tobaccocontrol.org/product_design/ PSC038.html.1
2 Kilburn KD [Unificd memo to C.I. Ayres on
107467542. URL:
www.tobaccocontrol.org/youth/
BrCaAT19770218.1.html

How to critique consultancy reports?
The recent proposals for smoke-free legis-
lation in many countries have spawned a multi-
tude of studies which attempt to predict the
financial impact of such legislation. As de-
scribed by Scoll et al in this issue of Tobacco
Control, many of these studies fail to achieve

basic quality standards and this is more likely
when the tobacco industry funds the study. However, findings from such flawed studies can
influence policy makers and it is essential
that public health advocates have strategies to
counter their impact.

1. Developments in scientific field 1976/77.
1. C.A.C. – Salamander. S & H Item
2. Correspondence to: Dr Sarah McGhee, Department of
Tobacco Control, University of Hong Kong, Hong Kong
Correspondence to: Dr Sarah McGhee, Department of
Tobacco Control, University of Hong Kong, Hong Kong.
smcghhee@hkuscc.hku.hk

References
1 Scoll M, LaI A, Hyland A, et al. Review of
the quality of studies on the economic effects
of smoke-free policies on the hospitality
2 Health and Welfare Bureau, Government of the
Hong Kong Special Administrative Region.
Document on the Proposed Legislative
Amendments to Smoking (Public Health)
Ordinance (Cap. 371).

Interest in nicotine replacement therapy among pregnant
smokers
In the UK nicotine replacement therapy
(NRT) may now be considered for those preg-
nant women who cannot otherwise stop
smoking.1 However, very little research has
been carried out with NRT during pregnancy
and the level of interest in using NRT is not
known.1 This letter reports the results of a
survey to assess the level of interest in using
NRT among pregnant smokers.

Across a seven month period pregnant
smokers were identified using the patient
administration system of a large district gen-
eral hospital in south west London. Ethical
approval was obtained and participants gave
good consent via the hospital staff. Women
identified as smokers at their first antenatal
booking visit were telephoned within one
week of this visit and invited to take part in
the survey. The interview took place during
the initial telephone call or during a further
call within 48 hours of the initial call. All sta-
tistical tests were two tailed.

Demographic information was obtained
from patient records. All the women were
asked “Can I just check, are you still smoking
at the moment?” (“yes” or “no”). Those still
smoking were asked “About how many a day
would you say you are smoking at the current
time?”, and “Are you thinking about stopping”?
(“yes” or “no”). Those expressing an
interest in stopping were asked “Do you
think you might want to stop in the next
month, or might you prefer to try a bit later
on?” “Would you be interested in receiving
some help from the hospital with stopping?”
(“yes” or “no”). Women stating an interest in
receiving help were asked “Some forms of
nicotine replacement therapy (NRT) may now
be considered for those pregnant smokers who feel they
wouldn’t be able to stop without it. Would you
choose to use NRT to help you to stop
smoking?” (“yes” or “no”).

Of the 207 smokers interviewed (fig 1) the
majority were not in professional/managerial occupations (85.0%, 176/207),
were white (75.8%, 157/207), and attended their first antenatal booking visit in the
hospital (66.7%, 138/207) rather than in the
community. The mean (SD) duration of preg-
nancy was 18.6 (5.6) weeks and the mean
(SD) reported number of cigarettes smoked
per day was 7.3 (6.1).

Of those women reporting that they were
thinking about stopping smoking 44.7% (67/
150) expressed an interest in using NRT.
Interest in NRT was higher among women
who reported smoking more cigarettes per
day (analysis of variance (ANOVA): F = 7.6,
Figure 1 Participant flow. PAS, patient administration system.

p = 0.006; mean (SD) cigarettes a day: interested in NRT (n = 67) = 9.5 (6.3), not interested in NRT (n = 83) = 7.1 (4.2). Following current licensing regulations, \( 39.3\% \) (59/150) of the women wanting to stop smoking reported smoking sufficient cigarettes per day (\( \geq 10 \)) to be considered eligible for NRT. Interest in using NRT was significantly higher for those smoking at least 10 cigarettes a day (\( \chi^2; \) \( p = 0.03 \); 10 or more cigarettes a day: interested in NRT = 55.9\% (33/59), less than 10 cigarettes a day: interested in NRT = 37.4\% (34/91)). Overall, 22\% (33/150) of those reporting wanting to stop smoking were both interested in NRT and eligible for NRT.

The results indicate a high level of interest in stopping smoking among pregnant women still smoking following their first antenatal booking and a moderate level of interest in using NRT. Fewer women were recorded as smokers at their first antenatal visit than would be expected from national data. This is likely to be because of the high number of Asian women in the local population. Encouragingly, those women who were heavier smokers, and were therefore eligible for NRT, showed most interest in NRT. Around a quarter of the smokers wanting to stop were both eligible for NRT and interested in using NRT. These findings add support to the argument for conducting further trials of NRT for pregnant smokers. The ultimate test of the acceptability of NRT for these women will be the degree to which NRT is utilised.

Voodoo cigarillos: bids in disguise?

As part of its routine monitoring of emerging tobacco products, “Trinkets & trash: artifacts of the tobacco epidemic”, a collection of current and historic tobacco marketing (www.trinketsandtrash.org), recently identified a new tobacco product called Voodoo cigarillos. They are exclusively manufactured in India for the US based Kretek International, a specialty tobacco distributor whose exclusive product line includes Djarum clove cigarettes, Darshan bids, and Dreams multi-coloured and flavoured cocktail cigarettes. The Voodoo cigarillos we obtained were flavoured and, as with bids, consisted of tobacco flakes wrapped in a leaf tied with a small string. Aside from a slightly larger and more uniform cylindrical shape, Voodoo cigarillos appear to be nearly identical to bids (fig 1). Only the name on the package would identify it as a cigar. US federal regulations define a cigar as any roll of tobacco wrapped in leaf tobacco or in any substance containing tobacco. Voodoo cigarillos appear to be wrapped in tendu leaf, which do not naturally contain tobacco.

So we ask, is this new product a cigarillo or a bid with new packaging? Federal regulation for conducting further trials of NRT for pregnant smokers.

References


C Delnevo, M Hrywna, M J Lewis, S Yulis University of Medicine and Dentistry of New Jersey School of Public Health, New Brunswick, New Jersey, USA

Correspondence to: Cristina Delnevo, 335 George Street, Liberty Plaza Suite 2200, New Brunswick, NJ 08903-2688, USA; delnevo@umdnj.edu

References


www.tobaccocontrol.com
Smoking in children’s picture books

The other day, one of the authors went to a public library with his 3 year old daughter to read some picture books to her. Various picture books, from classic to newly published, were available. Classic books are her favourite. First, she chose a book portraying adventures of a naughty monkey named Curious George (by HA Rey). He came to an industrialised country with a man in a yellow hat. My daughter pointed to a picture of the man holding a pipe between his lips. A smoking scene in a picture book for small children!

The next book she chose depicted an elephant named Babar (by Jean De Brunhoff) that fled from his country to Europe after his mother was killed by men. After coming back to his country with western technologies, he changed elephant society into Western-style society and became a king. Again, the King Babar was holding a pipe.

The third book was depicting a monster named Barbapapa living with François’ family (by Tison and Taylor). He had a mysterious ability to metamorphose into anything he desired. Unfortunately, in this attractive book, François’ father was always holding a pipe. Another supporting character was smoking a cigar. Smoking seems to be a symbol of manhood in these children’s picture books.

My daughter then opened books about Moominvalley (by Tove Jansson) and Tintin’s adventures (by Herge) in which some characters were smoking. Finally, I myself selected a book depicting Father Christmas (by Raymond Briggs). On Christmas Eve, Father Christmas delivered presents to children all over the world. After the labourious job, he took a rest smoking a cigar and a pipe.

Picture books reflect the norms or perceptions of our societies. These classic children’s books were first published in times when smoking was not widely acknowledged as harmful and a smoking male adult was one of the sex stereotypes. In addition, pipe smoking seems acceptable in such picture books compared with cigars or cigarettes which are seldom seen.

Caregivers frequently read picture books aloud to children at home, kindergartens, or daycare centres, which may have a considerable influence on preschool children. Young children receive strong messages from pictures. Seeing adult males smoking in picture books, they may take it as a desirable behaviour.

It would be unacceptable to remove smoking scenes from these classic books or eliminate the books themselves. What we can do is to become aware of the potential influence of these books and take a negative attitude to smoking when we read to children. Fortunately, the man in a yellow hat seems to have quit smoking in the new series of George’s adventures.

S Nakahara, S Wakai, M Ichikawa
Department of International Community Health, Graduate School of Medicine, The University of Tokyo, Japan

*Correspondence to: S Nakahara, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan; shinji@m.u-tokyo.ac.jp

Getting them while they’re young in China. Submitted by Professor TH Lam, Hong Kong.
BOOK REVIEW

Smoke-filled rooms: a postmortem on the tobacco deal


Smoke and mirrors

Cigarettes are a major cause of premature death. Cigarettes are addictive. Secondhand smoke can be annoying, but is really not enough of a health risk to justify banning smoking in indoor environments. Payments to states in the Master Settlement Agreement were unjustified since cigarettes are self financing. States actually save money because smokers die young. Lawsuits against the tobacco industry are without merit, since smokers have long known about the health risks. Continuing efforts to warn the public about the health risks of smoking are unwarranted since public awareness of these risks are now universal. Filters and low tar technology have made cigarette smoking safer, but make it annoying and is unlikely to encourage cigarette manufacturers to produce a less toxic cigarette. The government should focus on giving smokers information about the risks posed by different types of cigarettes, which would foster a market competition in the development of safer cigarettes while at the same time preserving individual choice.

Such are the views expressed by Harvard Law Professor W Kip Viscusi in his new book entitled Smoke-filled rooms. If cigarette smoking hasn’t already caused one to become short of breath, reading this book surely will. Viscusi’s selective presentation of data on what consumers do and don’t know about health risks of smoking, the dangers of secondhand smoke, the benefits of filtered and low tar cigarettes, and ultimately who should be held accountable for the massive death toll caused by smoking cigarettes is breathtaking. This book leaves one with the impression that the cigarette industry and not the American public has been the victim in what has been a massive money grab by greedy trial lawyers and lawyers who starred state attorneys general. It appears that Dr Viscusi has spent a few too many hours in smoked filled rooms to be able to reasonably separate fact from fiction. However, one fact is crystal clear—Viscusi is not the unbiased observer of the tobacco industry. He acknowledges that he has served as an expert witness for the cigarette industry. Thus, his diatribe against plaintiff lawyers, some of whom have risked their own personal fortunes to shed light on the lies and deceit of the cigarette industry, seem misplaced. Viscusi ought to take a look in the mirror.

Reading this book leaves one with the impression that the cigarette industry bears no responsibility for marketing what is admittedly a lethal and addictive product that results in the premature death of one out of every two users. Viscusi dismisses the evidence that the cigarette industry has knowingly misrepresented the dangers of smoking to the American public on the grounds that smokers knew everything they needed to know about smoking in order to make an informed choice. However, one needs to question whether this assumption is correct. The evidence presented in chapter 7 to support the claim that smokers are fully informed is far from compelling. Viscusi misrepresents polling data showing that the public has long been aware of medical reports linking smoking and cancer as evidence that smokers were fully informed of health risks. He must surely recognise that having a general awareness that smoking causes cancer does not necessarily translate into a belief that one is at a higher risk of developing cancer. In fact studies conducted by Viscusi himself demonstrate that smokers as a group are less likely to perceive health risks from smoking compared to non-smokers. He also fails to mention the knowledge deficits that many smokers have regarding compensatory smoking, the lack of benefits from smoking filtered and low tar cigarettes, and secondhand smoke.

Viscusi’s discussion of the factors involved in youth smoking behaviour represents an exercise in selective recall, laying the blame for youth smoking mainly on parents. Hardly a mention is made of the billions of dollars spent annually by cigarette companies to advertise and promote cigarettes. Viscusi also ignores the mountains of internal industry documents that openly discussed the importance of the youth smoking market to the economic viability of the cigarette industry. Instead he accepts at face value the industry’s line that they don’t want kids to smoke. Viscusi’s remedy for the youth smoking problem is to get parents to do more to keep their kids from smoking and to enact policies to prohibit the sale of unconventional cigarettes like bids. The discussion of bids is especially odd since heders smoke these products; instead teenagers smoke Marlboro, Newport, and Camel. Thus, while one can hardly argue with Viscusi’s plea for better parenting, his failure to recommend stronger measures to curb how tobacco companies market their cigarettes to attract the attention of youthful smokers makes the sincerity of his recommendations suspect.

Viscusi’s chapter on the health risks associated with secondhand tobacco smoke is grossly uninformed. Much of this chapter reads like it was drawn from industry sponsored websites that have been designed to spread misinformation, downplaying the well documented scientific evidence linking secondhand smoke exposure to a wide array of health risk. Remarkably, Viscusi suggests that limits on indoor smoking are unjustified and bad for the economy because such restrictions cause smokers to consume fewer cigarettes, and, therefore, “losses accrue to society in terms of foregone taxes”.

Viscusi’s sharp criticism of current public health campaigns to warn the public about the health risks of smoking defies common sense. According to Viscusi, since public awareness of the health risks of smoking are nearly universal, there is no need to keep repeating these messages. In fact he argues that such efforts are counterproductive because people are likely to form unrealistic risk perceptions about smoking. Such reasoning is illogical. By analogy, if one were to accept Viscusi’s premise that once the public recognises the health risks of smoking there is no need to reinforce health messages, then one would also have to accept the idea that there is no need to spend a dime advertising Marlboro cigarettes since the Marlboro Man is nearly universally recognised. Apparently, cigarette manufacturers don’t accept Viscusi’s logic and nor should the public. Viscusi’s criticism of current public health campaigns to inform the public of the dangers of smoking use. Viscusi’s criticism of the current wave of edgy in your face counter-advertising campaigns ignores the evidence that these programmes are actually reducing cigarette consumption. Instead of continuing these effective public health campaigns, Viscusi recommends that the government refocus its efforts towards giving smokers information about the risks posed by different types of cigarettes in the hope that this would move smokers to use less toxic cigarettes.

Viscusi is correct in noting an important deficiency of the Master Settlement Agreement that has made it difficult for new tobacco companies to enter the market, thus dampening competition for the development of potentially safer tobacco products. However, his credibility on this subject is diminished by his acceptance of the view that declining cigarette consumption in the USA since the 1960s corresponds directly to increased efforts to inform the public of the dangers of tobacco use. Viscusi’s criticism of the current wave of edgy in your face counter-advertising campaigns ignores the evidence that these programmes are actually reducing cigarette consumption. Instead of continuing these effective public health campaigns, Viscusi recommends that the government refocus its efforts towards giving smokers information about the risks posed by different types of cigarettes in the hope that this would move smokers to use less toxic cigarettes.

In summary, Smoke-filled rooms reads more like a legal brief written by a team of tobacco industry lawyers instead of a thoughtful commentary on the legal, financial, and social consequences of smoking. As such this book is a must read for plaintiffs’ attorneys, but for the rest of us we should stick with “smoke-free rooms”.

K M Cummings

References

1 Ayanian JZ, Cleary PD. Perceived risks of heart disease and cancer among cigarette smokers. JAMA 1999; 281: 1019-21

www.tobaccocontrol.com


Hurt RD, Robertson CR. Prying open the door to the cigarette industry’s secrets about nicotine – the Minnesota tobacco trial. JAMA 1998;280:1173–81.


Disclosure
K Michael Cummings is not an unbiased observer of Dr Viscusi’s research and writings. He has served as a paid expert witness on behalf of plaintiffs counsel in several of the same cases in which Dr Viscusi also served as an expert for the cigarette industry. Dr Cummings is currently employed as a senior research scientist and is chairman of the Department of Health Behavior in the Division of Cancer Prevention and Population Sciences at the Roswell Park Cancer Institute in Buffalo, New York, USA. His salary support comes primarily from Roswell Park Cancer Institute and from research funding provided by the National Cancer Institute, the Robert Wood Johnson Foundation, the American Legacy Foundation, and New York State Department of Health. Dr Cummings serves on the medical advisory board for the Flight Attendant Medical Research Institute (FAMRI) and has served on various scientific advisory boards and grant review committees for National Institutes of Health, Centers for Disease Control and Prevention, American Cancer Society, Canadian National Cancer Institute, Robert Wood Johnson Foundation, and state and local health agencies for which he has received honoraria. Dr Cummings has also received honoraria and has accepted hospitality and on a few occasions, travel costs, from pharmaceutical companies making tobacco dependence treatment products.

The lighter side

©The New Yorker Collection. Mark Stevens from Cartoonbank.com. All Rights Reserved.